Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Avidity Biosciences Inc shares valued at $619,444 were sold by Boyce Sarah on Jan 07 ’26. At $72.23 per share, Boyce Sarah sold 8,576 shares. The insider’s holdings dropped to 283,394 shares worth approximately $20.59 million following the completion of this transaction.
Also, Calderaro Charles III sold 3,727 shares, netting a total of over 269,201 in proceeds. Following the sale of shares at $72.23 each, the insider now holds 49,797 shares.
Before that, McCarthy Teresa had sold 1,965 shares from its account. In a trade valued at $141,932, the Chief Human Resources Officer traded Avidity Biosciences Inc shares for $72.23 each. Upon closing the transaction, the insider’s holdings decreased to 1,965 shares, worth approximately $8.49 million.
As published in their initiating research note from Roth Capital on September 17, 2025, Avidity Biosciences Inc [RNA] has been a Buy and the price target has been revised to $62. As of June 24, 2025, Bernstein has initiated its “an Outperform” rating for RNA. Earlier on June 17, 2025, Wolfe Research initiated its rating. Their recommendation was “an Outperform” for RNA stock.
Analyzing RNA Stock Performance
On last trading session, Avidity Biosciences Inc [NASDAQ: RNA] rose 0.25% to $72.65. The stock’s lowest price that day was $72.45, but it reached a high of $72.67 in the same session. During the last five days, there has been a surge of approximately 0.30%. Over the course of the year, Avidity Biosciences Inc shares have jumped approximately 151.21%.
Is Avidity Biosciences Inc subject to short interest?
Stocks of Avidity Biosciences Inc saw a sharp steep in short interest on 2025-12-31 dropping by 73782.0 shares to 8.79 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 8.87 million shares. A decline of -0.84% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.09 of the overall float, the days-to-cover ratio (short ratio) decline to 4.09.
Which companies own the most shares of Avidity Biosciences Inc (RNA)?
In terms of Avidity Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, down nearly -0.65% from the previous closing price of $72.47. Analysts anticipate Avidity Biosciences Inc stock to reach 96 by 2026, with the lowest price target being 72. In spite of this, 6 analysts ranked Avidity Biosciences Inc stock as Buy at the end of 2026. On June 11, 2025, Raymond James assigned a price target of “a Strong buy” to the stock and initiated coverage with a $65.
